Kiora Stock Buy Hold or Sell Recommendation

KPRX
 Stock
  

USD 7.82  0.71  9.99%   

Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Kiora Pharmaceuticals is 'Strong Sell'. Macroaxis provides Kiora Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding KPRX positions. The advice algorithm takes into account all of Kiora Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site.
  
The advice is provided from Kiora Pharmaceuticals' buy-and-hold perspective. Please see Kiora Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as Kiora and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards Kiora Pharmaceuticals.

Execute Kiora Pharmaceuticals Buy or Sell Advice

The Kiora recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Kiora Pharmaceuticals. Macroaxis does not own or have any residual interests in Kiora Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Kiora Pharmaceuticals' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Kiora PharmaceuticalsBuy Kiora Pharmaceuticals
Strong Sell

Volatility

Details

Hype Condition

Details

Current Valuation

Details

Odds of Distress

Details

Economic Sensitivity

Details

Analyst Consensus

Details

Reporting Quality (M-Score)

Details
For the selected time horizon Kiora Pharmaceuticals has a Mean Deviation of 8.25, Standard Deviation of 15.62 and Variance of 243.87
We provide investment recommendation to complement the last-minute expert consensus on Kiora Pharmaceuticals. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the entity's potential to grow using all technical and fundamental data available at the time. To make sure Kiora Pharmaceuticals is not overpriced, please verify all Kiora Pharmaceuticals fundamentals, including its net income, as well as the relationship between the book value per share and market capitalization . Given that Kiora Pharmaceuticals has a number of shares shorted of 175.99 K, we recommend you to check Kiora Pharmaceuticals market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your last-minute risk tolerance and investing horizon.

Kiora Pharmaceuticals Trading Alerts and Improvement Suggestions

Kiora Pharmaceuticals generated a negative expected return over the last 90 days
Kiora Pharmaceuticals has high historical volatility and very poor performance
Kiora Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 12.06 K. Net Loss for the year was (15.33 M) with loss before overhead, payroll, taxes, and interest of (5.14 M).
Kiora Pharmaceuticals currently holds about 5.07 M in cash with (10.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39.
Latest headline from www.benzinga.com: Infinite Group Inc. Stock Looks Appreciably Undervalued After Announcing Strategic Integrations For Its N - Benzinga

Kiora Pharmaceuticals current analysts advice

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kiora analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kiora analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Mean Price7.00
Target Median Price6.00
Target High Price15.00
Recommendation Mean2.00
Number Of Analyst Opinions4
Target Low Price1.00
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

Kiora Pharmaceuticals Returns Distribution Density

The distribution of Kiora Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Kiora Pharmaceuticals' future price movements. The chart of the probability distribution of Kiora Pharmaceuticals stock daily returns describes the distribution of returns around its average expected value. We use Kiora Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Kiora Pharmaceuticals returns is essential to provide solid investment advice for Kiora Pharmaceuticals.
Mean Return-0.47Value At Risk-17.04
Potential Upside17.42Standard Deviation15.62
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Kiora Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Kiora Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Kiora Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kiora Pharmaceuticals backward and forwards among themselves. Kiora Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Kiora Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Geode Capital Management LlcCommon Shares547.1 K257 K
Vanguard Group IncCommon Shares67.2 K31 K
Price T Rowe Associates IncCommon Shares51.3 K24 K
Citadel Advisors LlcCommon Shares46.4 K22 K
Renaissance Technologies LlcCommon Shares41.8 K20 K
Ubs Group AgCommon Shares28.9 K13 K
Blackrock IncCommon Shares21 K10 K
Note, although Kiora Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Kiora Pharmaceuticals Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Kiora Pharmaceuticals or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Kiora Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Kiora stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over DOW
-0.32
β
Beta against DOW2.39
σ
Overall volatility
15.90
Ir
Information ratio -0.03

Kiora Pharmaceuticals Volatility Alert

Kiora Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize Kiora Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about Kiora Pharmaceuticals volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Kiora Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Kiora Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Kiora Pharmaceuticals Fundamentals Vs Peers

Comparing Kiora Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Kiora Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Kiora Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Kiora Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Kiora Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Kiora Pharmaceuticals by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Kiora Pharmaceuticals to competition
FundamentalsKiora PharmaceuticalsPeer Average
Return On Equity(128.01) %(0.31) %
Return On Asset(33.05) %(0.14) %
Current Valuation(2.99 M)16.62 B
Shares Outstanding12.65 M571.82 M
Shares Owned by Insiders2.00 %10.09 %
Shares Owned by Institutions47.78 %39.21 %
Number of Shares Shorted175.99 K4.71 M
Price to Book5.17 X9.51 X
Price to Sales385.82 X11.42 X
Revenue12.06 K9.43 B
Gross Profit(5.14 M)27.38 B
EBITDA(10.07 M)3.9 B
Net Income(15.33 M)570.98 M
Cash and Equivalents5.07 M2.7 B
Cash per Share0.39 X5.01 X
Total Debt158.31 K5.32 B
Debt to Equity0.014 %48.70 %
Current Ratio2.60 X2.16 X
Book Value Per Share1.38 X1.93 K
Cash Flow from Operations(10.94 M)971.22 M
Short Ratio0.71 X4.00 X
Earnings Per Share(1.44) X3.12 X
Number of Employees1418.84 K
Beta0.81-0.15
Market Capitalization89.96 M19.03 B
   Payment of 108 shares by Romano Sarah of Kiora Pharmaceuticals subject to Rule 16b-3 [view details]

Kiora Pharmaceuticals Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Kiora . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Kiora Pharmaceuticals Buy or Sell Advice

When is the right time to buy or sell Kiora Pharmaceuticals? Buying financial instruments such as Kiora Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Kiora Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Driverless Cars Thematic Idea Now

Driverless Cars
Driverless Cars Theme
Large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries that are directly or indirectly involved in shaping up the development and marketing of self-driving vehicles. The Driverless Cars theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
View All  Next Launch
Please see Kiora Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for analysis

When running Kiora Pharmaceuticals price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Is Kiora Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiora Pharmaceuticals. If investors know Kiora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiora Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kiora Pharmaceuticals is measured differently than its book value, which is the value of Kiora that is recorded on the company's balance sheet. Investors also form their own opinion of Kiora Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiora Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiora Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiora Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiora Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Kiora Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiora Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.